Smith Salley Wealth Management
Source: SEC Form 13F · as of Mar 2026Smith Salley Wealth Management holds 14 biotech & pharma companies tracked by BioSniper, totaling $132.7M in value as of Mar 2026 (SEC Form 13F).
Companies held
14
Total value held
$132.7M
| Company | Shares | Value |
|---|---|---|
| ABBVAbbVie Inc. | 160,791 | $35.0M |
| ABTABBOTT LABORATORIES | 189,613 | $19.5M |
| LLYELI LILLY & Co | 20,967 | $19.3M |
| JNJJOHNSON & JOHNSON | 57,834 | $14.1M |
| AZNASTRAZENECA PLC | 68,919 | $13.6M |
| ELVElevance Health Inc. | 39,514 | $11.6M |
| MRKMerck & Co., Inc. | 43,935 | $5.3M |
| UNHUnitedHealth Group Incorporated Common Stock (DE) | 15,850 | $4.3M |
| AMGNAMGEN INC | 11,102 | $3.9M |
| PMPhilip Morris International Inc | 15,246 | $2.5M |
| IQVIQVIA Holdings Inc. | 12,987 | $2.2M |
| BMYBRISTOL MYERS SQUIBB CO | 10,549 | $640K |
| NVSNovartis AG | 3,892 | $595K |
| GILDGILEAD SCIENCES, INC. | 1,480 | $206K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.